News
07-03-2008, 02:10 AM
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that its lead product candidate bavituximab achieved the pre-specified Stage 1 primary endpoint in its ongoing Phase II clinical trial in patients with metastatic breast cancer. The trial is an open-label, Simon two-stage design to evaluate the safety and efficacy of a combination of bavituximab and docetaxel in metastatic breast cancer patients.
More... (http://www.medicalnewstoday.com/articles/113736.php)
More... (http://www.medicalnewstoday.com/articles/113736.php)